Results 161 to 170 of about 70,663 (209)
Some of the next articles are maybe not open access.
Chimeric Antigen Receptor T-cells (CARs) in Cancer Treatment
Current Molecular Pharmacology, 2022Background: Cancer is one of the leading causes of death worldwide. Chemotherapy, radiation therapy, and stem cell transplantation were the main cancer treatment approaches for several years but due to their limited effectiveness, there was a constant search for new therapeutic approaches.
Wissam Zam, Amany Assaad
openaire +2 more sources
Imaging Chimeric Antigen Receptor (CAR) Activation
2020The chimeric antigen receptor (CAR) has been extensively exploited in cancer immunotherapy. In spite of the success of CAR T cells in clinical applications, the molecular mechanism underlying CAR-T cell activation remains unclear. Key questions remain: how are CARs activated by tumor antigens?
Kendra A, Libby, Xiaolei, Su
openaire +2 more sources
Chimeric Antigen Receptor (CAR) T Cell Therapy for Glioblastoma
2022Genetic modification of T cells to express chimeric antigen receptors (CARs) has yielded remarkable clinical outcomes and initiated a novel era for cancer immunotherapy. The impressive clinical responses seen in hematologic malignancies have led to the investigation of CAR T cells in solid tumors but attaining similar results has been challenging to ...
Amitesh, Verma, Sarwish, Rafiq
openaire +2 more sources
Chimeric antigen receptor (CAR) T-cell therapy for multiple myeloma
Pharmacology & Therapeutics, 2022Although treatment outcomes of multiple myeloma patients have improved significantly during the last two decades, myeloma is still an incurable disease. There are newly emerging immunotherapies to treat multiple myeloma including monoclonal antibodies, antibody-drug conjugate, bispecific antibodies, and chimeric antigen receptor (CAR) T cell therapy ...
Taewoong, Choi, Yubin, Kang
openaire +2 more sources
Chimeric Antigen Receptor (CAR) T Cells
2015Recent advances in cellular engineering techniques coupled with modern chimeric antigen receptors (CARs) now permit the efficient targeting and killing of malignant cells using patients’ own T cells. Freedom from MHC restriction by relying most commonly on single chain variable fragments of monoclonal antibodies for antigen recognition rather than T ...
Daniel W. Lee, Alan S. Wayne
openaire +1 more source
Chimeric Antigen Receptor (CAR) Redirected T Cells
2020Adoptive immunotherapy with chimeric antigen receptor (CAR) redirected T cells is a new therapeutic paradigm with a new class of therapeutic “drugs” producing complete and lasting remissions in patients with certain subtypes of so far refractory B cell malignancies.
Astrid Holzinger, Hinrich Abken
openaire +1 more source
Infectious complications of chimeric antigen receptor (CAR) T-cell therapies
Seminars in Hematology, 2023CAR T-cells have revolutionized the treatment of many hematological malignancies. Thousands of patients with lymphoma, acute lymphoblastic leukemia, and multiple myeloma have received this "living medicine" and achieved durable remissions. Their place in therapy continues to evolve, and there is ongoing development of new generation CAR constructs, CAR
openaire +2 more sources
Manufacturing Chimeric Antigen Receptor (CAR) T Cells for Adoptive Immunotherapy
Journal of Visualized Experiments, 2019Adoptive immunotherapy holds promise for the treatment of cancer and infectious disease. We describe a simple approach to transduce primary human T cells with chimeric antigen receptor (CAR) and expand their progeny ex vivo. We include assays to measure CAR expression as well as differentiation, proliferative capacity and cytolytic activity.
Saba, Ghassemi, Michael C, Milone
openaire +2 more sources
In vivo chimeric antigen receptor (CAR)-T cell therapy
Nature Reviews Drug DiscoveryChimeric antigen receptor (CAR)-T cell therapy has transformed the outcomes of patients with haematological malignancies, yet its use is limited by labour-intensive manufacturing, constrained production capacity and variable clinical performance. In vivo CAR-T cell engineering, in which CAR-T cells are generated directly inside the patient's body ...
Adrian Bot +14 more
openaire +2 more sources
Chimeric-antigen Receptor T (CAR-T) Cell Therapy for Leukemia
Proceedings of the 2020 10th International Conference on Biomedical Engineering and Technology, 2020Leukemia is known as a kind of "blood cancers" that is caused by the disorders of hematopoietic stem cells (HSCs). It is one of the most common cancers that spreads all around the world. Leukemia causes countless people's deaths every year, and people have been working on improving leukemia therapies very hard for years.
openaire +1 more source